General Information of Drug (ID: DMUVON0)

Drug Name
PNT-2258 Drug Info
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMUVON0

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
BCL-2 messenger RNA (BCL2 mRNA) TTFOUV4 BCL2_HUMAN Not Available [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
BCL-2 messenger RNA (BCL2 mRNA) DTT BCL2 3.963 4.739 4.146 4.878
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diffuse large B-cell lymphoma
ICD Disease Classification 2A81
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
BCL-2 messenger RNA (BCL2 mRNA) DTT BCL2 8.27E-03 0.06 0.13
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01733238) Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of ProNAi.